All In Biotech

Drug Trial Radar · NCT05750628

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

327

Planned (sponsor's estimate)

Start

Jan 23, 2024

Primary completion

Jun 9, 2026

Study completion Jun 23, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

  • INE963Drug

    oral INE963

  • KAE609 (Cipargamin)Drug

    oral KAE609 (Cipargamin)

  • SoC (Coartem)Drug

    SoC (Coartem)

  • KLU156Drug

    oral sachet KLU156 (KAF156 + lumefantrine)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: parasite clearance time (PCT)Time frame: up to Day 7
  2. Part B and C: polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR)Time frame: Day 29

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Banfora, Burkina Faso · Recruiting

  • Novartis Investigative Site

    Nanoro, Burkina Faso · Recruiting

  • Novartis Investigative Site

    Abidjan, Côte d’Ivoire · Recruiting

  • Novartis Investigative Site

    Azaguié, Côte d’Ivoire · Recruiting

  • Novartis Investigative Site

    Lambaréné, Gabon · Recruiting

  • Novartis Investigative Site

    Libreville, Gabon · Recruiting

  • Novartis Investigative Site

    Kintampo, Ghana · Recruiting

  • Novartis Investigative Site

    Navrango, Ghana · Recruiting

  • Novartis Investigative Site

    Kisumu, Kenya · Recruiting

  • Novartis Investigative Site

    Ahero, Kisumu County, Kenya · Recruiting

  • Novartis Investigative Site

    Kampala, Uganda · Recruiting

  • Novartis Investigative Site

    Tororo, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.